Posted by Michael Wonder on 18 Dec 2019
Proposal to fund mepolizumab for the treatment of severe refractory eosinophilic asthma
18 December 2019 - PHARMAC is seeking feedback on a proposal to fund mepolizumab (Nucala), a new treatment for severe refractory eosinophilic asthma, from 1 April 2020 through a provisional agreement with GlaxoSmithKline.
The agreement with GSK would also include amendments to the contractual arrangements for warfarin sodium (Marevan) and for lamotrigine (Lamictal) 2 mg and 5 mg tablets.
There would be no changes to the funding of these products, but the price would change.
